Sigilon Therapeutics, Inc.
NASDAQ: SGTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Rogerio Vivaldi Coelho MBA
- Employees
- 62
- Headquarters
- Cambridge, United States
- IPO year
- 2020
- Market cap
- $56.2M
- Website
- https://www.sigilon.com
Loading SGTX…
Loading profile data…Frequently asked questions about SGTX
What does Sigilon Therapeutics, Inc. (SGTX) do?
Cambridge, Massachusetts-based Sigilon Therapeutics, Inc., established in 2015, functions as a clinical-stage biotechnology firm dedicated to creating lasting solutions for patients grappling with chronic health conditions. Its primary investigational therapy, SIG-001, is currently undergoing Phase I/II clinical assessment to prevent bleeding ep...
Where does SGTX trade?
Sigilon Therapeutics, Inc. (SGTX) trades on the NASDAQ Global Select.
What sector is SGTX in?
Sigilon Therapeutics, Inc. (SGTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Sigilon Therapeutics, Inc.?
Rogerio Vivaldi Coelho MBA is the chief executive officer of Sigilon Therapeutics, Inc. (SGTX).
Where is Sigilon Therapeutics, Inc. headquartered?
Sigilon Therapeutics, Inc. is headquartered in United States.
Does SGTX pay a dividend?
Sigilon Therapeutics, Inc. (SGTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SGTX go public?
Sigilon Therapeutics, Inc. (SGTX) completed its initial public offering in 2020.